...
首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model.
【24h】

Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model.

机译:在他的同基因肾移植模型中,用他克莫司和雷帕西汀的组合预处理供体,以减少缺血-再灌注损伤。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Reperfusion injury remains one of the major problems in transplantation. Repair from ischaemic acute renal failure (ARF) involves stimulation of tubular epithelial cell proliferation. The aim of this exploratory study was to evaluate the effects of preconditioning donor animals with rapamycin and tacrolimus to prevent ischaemia-reperfusion (I/R) injury. Twelve hours before nephrectomy, the donor animals received immunosuppressive drugs. The animals were divided into four groups, as follows: group 1 control: no treatment; group 2: rapamycin (2 mg/kg); group 3 FK506 (0, 3 mg/kg); and group 4: FK506 (0, 3 mg/kg) plus rapamycin (2 mg/kg). The left kidney was removed and after 3 h of cold ischaemia, the graft was transplanted. Twenty-four hours after transplant, the kidney was recovered for histological analysis and cytokine expression. Preconditioning treatment with rapamycin or tacrolimus significantly reduced blood urea nitrogen and creatinine compared with control [blood urea nitrogen (BUN): P < 0.001 versus control and creatinine: P < 0.001 versus control]. A further decrease was observed when rapamycin was combined with tacrolimus. Acute tubular necrosis was decreased significantly in donors treated with immunosuppressants compared with the control group (P < 0.001 versus control). Moreover, the number of apoptotic nuclei in the control group was higher compared with the treated groups (P < 0.001 versus control). Surprisingly, only rapamycin preconditioning treatment increased anti-apoptotic Bcl2 levels (P < 0.001). Finally, inflammatory cytokines, such as tumour necrosis factor (TNF)-alpha and interleukin (IL)-6, showed lower levels in the graft of those animals that had been pretreated with rapamycin or tacrolimus. This exploratory study demonstrates that preconditioning donor animals with rapamycin or tacrolimus improves clinical outcomes and reduce necrosis and apoptosis in kidney I/R injury.
机译:再灌注损伤仍然是移植中的主要问题之一。缺血性急性肾衰竭(ARF)的修复涉及刺激肾小管上皮细胞增殖。这项探索性研究的目的是评估雷帕霉素和他克莫司预处理供体动物预防缺血再灌注(I / R)损伤的作用。肾切除术前十二小时,供体动物接受了免疫抑制药物。将动物分为四组,如下:第1组对照:不治疗;不进行任何处理。第2组:雷帕霉素(2 mg / kg);第3组FK506(0,3 mg / kg);第4组:FK506(0,3 mg / kg)加雷帕霉素(2 mg / kg)。取出左肾,冷缺血3小时后,移植移植物。移植后二十四小时,恢复肾脏用于组织学分析和细胞因子表达。与对照组相比,雷帕霉素或他克莫司的预处理显着降低了血液中的尿素氮和肌酐[血尿素氮(BUN):与对照相比,P <0.001和肌酐:与对照相比,P <0.001]。雷帕霉素与他克莫司合用时观察到进一步降低。与对照组相比,接受免疫抑制剂治疗的供者的急性肾小管坏死明显减少(与对照相比,P <0.001)。此外,与治疗组相比,对照组的凋亡核数目更高(与对照组相比,P <0.001)。出人意料的是,只有雷帕霉素预处理可以提高抗凋亡Bcl2水平(P <0.001)。最后,炎性细胞因子,例如肿瘤坏死因子(TNF)-α和白介素(IL)-6,在经过雷帕霉素或他克莫司预处理的那些动物的移植物中显示出较低的水平。这项探索性研究表明,用雷帕霉素或他克莫司预处理供体动物可改善临床结局,并减少肾脏I / R损伤的坏死和细胞凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号